IP Library Granted Patent US 8,119,635
Granted Patent B2
US 8,119,635 · App. 12/543,822 · Granted Feb 21, 2012

Diazabicyclic central nervous system active agents

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,119,635
App. No.
12/543,822
Granted
Feb 21, 2012
Kind
B2
Abstract

Compounds of formula I pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.

Claims (18)

1. A compound of formula V

or pharmaceutically acceptable salts thereof, wherein

Y is selected from the groups consisting of a covalent bond, CH 2 , and CH 2 CH 2 ;

Z is selected from the groups consisting of a covalent bond, CH 2 , and CH 2 CH 2 , provided that when Y is CH 2 CH 2 , then Z is a covalent bond and further provided that when Z is CH 2 H 2 , then Y is a covalent bond;

R 1 is selected from the group consisting of

R 3 is selected from the group consisting of hydrogen, alkyl, and halogen;

R 4 is selected from the group consisting of hydrogen, alkoxy, alkyl, amino, halogen, and nitro;

R 5 is selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylthio, alkynyl, amino, aminoalkyl, aminocarbonyl, aminocarbonylalkyl, aminosulfonyl, carboxy, carboxyalkyl, cyano, cyanoalkyl, formyl, formylalkyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, mercaptoalkyl, nitro, 5-tetrazolyl, —NR 6 S(O) 2 R 7 , —C(NR 6 )NR 7 R 8 , —CH 2 C(NR 6 )NR 7 R 8 , —C(NOR 6 )R 7 , —C(NCN)R 6 , —C(NNR 6 R 7 )R 8 , —S(O) 2 OR 6 , and —S(O) 2 R 6 ;

R 6 , R 7 , and R 8 are independently selected from the group consisting of hydrogen and alkyl; and

R 9 is selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, amino, aminoalkyl, aminocarbonylalkyl, benzyloxycarbonyl, cyanoalkyl, dihydro-3-pyridinylcarbonyl, hydroxy, hydroxyalkyl, and phenoxycarbonyl.

2. A compound or salt thereof according to claim 1 wherein Y is a covalent bond and Z is a covalent bond.

3. A compound or salt thereof according to claim 1 wherein Y is CH 2 and Z is a covalent bond.

4. A compound or salt thereof according to claim 1 wherein Y is a covalent bond and Z is CH 2 .

5. A compound or salt thereof according to claim 1 wherein Y is CH 2 CH 2 and Z is a covalent bond.

6. A compound or salt thereof according to claim 1 wherein Y is CH 2 and Z is CH 2 .

7. A compound or salt thereof according to claim 1 wherein Y is a covalent bond and Z is CH 2 CH 2 .

8. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically acceptable carrier.

9. A method of treating a disorder selected from the group consisting of pain, Alzheimer's disease, Parkinson's disease, attention deficit hyperactivity disorder, depression, nicotinic withdrawal syndrome, Tourette's syndrome and schizophrenia, the method comprising administering a therapeutically effective amount of a compound or salt of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 030167/0733 →